The treatment landscape for complement-mediated kidney diseases (CMKDs) is rapidly evolving. Targeted therapies aimed at specific points within the complement pathway have recently been approved or are in late-stage clinical development. Data indicate these therapies are effective in treating CMKDs without some of the accompanying risks brought by generalized immunosuppression, providing new hope for patients affected by these diseases. Don’t miss the chance to hear from two leading nephrologists as they review the latest data for the safety and efficacy of targeted CMKD therapies, including clinical evidence presented at ASN 2024 Kidney Week. Discussion of expert strategies will equip you with the tools needed to integrate these treatments into clinical practice as they become available.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/exploring-new-frontier-cmkd-treatment-latest-evidence-new-emerging-targeted
- Start Date: 2024-11-26 06:00:00
- End Date: 2024-11-26 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.75 hours
AMA PRA Category 1 Credit™️: 0.75 hours
Nursing: 0.75 hours
Pharmacy: 0.75 hours - Commercial Support: Source: Novartis Corporation Pharmaceuticals - Amount: 44916.67 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all